Objective:To evaluate clinical efficacy by traditional Chinese combined with western therapy to treat upper extremity edema after breast cancer surgery.The clinical efficacy was described by the effective rate and the...Objective:To evaluate clinical efficacy by traditional Chinese combined with western therapy to treat upper extremity edema after breast cancer surgery.The clinical efficacy was described by the effective rate and the change of peripheral diameter of the affected limb.Methods:National Knowledge Internet(CNKI),Wan Fang Digital Journals(Wan Fang),VIP Chinese periodical service platform(VIP),Chinese biomedical literature service system(CBM),PubMed and EMBASE were searched on computer.And clinical randomized controlled trials(RCT)of the treatment of upper extremity edema after breast cancer surgery with integration of Chinese and western treatment were selected.The time was from January 2011 to May 2020.Upper extremity edema after breast cancer surgery was the first key word and the second was traditional Chinese combined with western therapy.Note Express was used to screen and extract literature.Bias risks of all the literature included in the study were evaluated and analyzed by RevMan5.3 software.Results:10 randomized controlled clinical tests,644 patients in conformity to the inclusion criteria,9 for the observation of curative effectiveness,5 of changes in limb circumference.322 cases were included in the observation group and the same number of cases in the control group,all of which were in Chinese.The results expressed that the curative effect in the observation group was 91.1%,and it was higher than the curative effect in the control group treated by single western treatment obviously,and it was only 68.9%[95%CI(1.22,1.44),Z=6.55,P<0.00001].The peripheral diameter shrinking degree of the affected limb in the observation group was also clearly higher than that in the control group which was healed by simple western treatment[95%CI(-0.98,-0.64),Z=9.40,P<0.00001].Conclusion:Traditional Chinese combined with western therapy treating upper extremity edema after the surgery of breast cancer had a notable clinical effect,which treated the disease and effectively lessened the peripheral diameter of the affected limb.The method was worthy of clinical application.However,owing to the low quality of the included documents,further discussion and learning were still needed.展开更多
Objective To observe the clinical efficacy and safety of WenYang HuoXue Washing Prescription （WYHX） in the treatment of upper limb edema after breast cancer surgery. Methods： Seventy-eight patients with upper ext...Objective To observe the clinical efficacy and safety of WenYang HuoXue Washing Prescription （WYHX） in the treatment of upper limb edema after breast cancer surgery. Methods： Seventy-eight patients with upper extremity edema after operation of breast cancer with Yin Syndrome were given wet compress with prescription and nursing guidance. The symptom score of affected extremity was observed before and 14 days after treatment, and the total effective rate was evaluated. Results： Twenty-three cases were markedly effective, 41 cases were effective and 14 cases were Invalid. The total effective rate was 82.1%. There was no significant difference between the two groups according to stage I and stage II of edema （P 〉 0.05）. Conclusion： WYHX can effectively improve the discomfort symptoms of upper limb edema and cold after breast cancer surgery, and is worthy of clinical application.展开更多
目的:探讨身体质量指数(body mass index,BMI)与放疗前、后乳腺癌相关淋巴水肿(breast cancer related lymphedema,BCRL)的相关性。方法:分析2013年11月至2015年2月281例于河北医科大学第四医院收治的单侧乳腺癌术后女性患者的前瞻性临...目的:探讨身体质量指数(body mass index,BMI)与放疗前、后乳腺癌相关淋巴水肿(breast cancer related lymphedema,BCRL)的相关性。方法:分析2013年11月至2015年2月281例于河北医科大学第四医院收治的单侧乳腺癌术后女性患者的前瞻性临床资料,根据BMI<25、25~27、BMI≥28分为BMI低组(n=94)、中组(n=89)、高组(n=98),比较健患侧上肢体积差(upper limb volume difference,ULVD),采用广义估计方程(GEE)模型和线性逻辑回归模型进行单因素和多因素分析,评估放疗对BCRL(定义为ULVD≥200 m L)的影响,并与其他BMI分界值分组结果进行比较。结果:放疗前、后ULVD平均值分别为40.6、42.9 m L,中位值均为30.0 m L,二者之间差异无统计学意义(P>0.05)。放疗前(2例缺失)BMI低、中、高组的BCRL发生率分别为2.2%(2/93)、6.8%(6/88)、13.3%(13/98),放疗后(1例缺失)分别为1.1%(1/93)、12.4%(11/89)、12.2%(12/98),GEE模型多因素分析显示放疗未增加BCRL率(P=0.529)。线性逻辑回归模型多因素分析显示,与BMI低组相比中组和高组放疗前(RR=4.199,P=0.693和RR=10.999,P=0.002)、放疗后(RR=13.287,P=0.047和RR=14.308,P=0.029)的BCRL发生率差异具有统计学意义。按BMI<25、25~29、BMI≥30分组,分析结果与以上类似。结论:乳腺癌患者术后放疗发生BCRL,中国乳腺癌患者理想的BMI<28,与国外欧美患者为主的BMI<30不同。展开更多
基金General project of national natural science foundation(No.81573989,81403408)Project for national talent inheritors of traditional Chinese medicine[No.(2019)36]Project for leading talent of hygiene and health of Shandong province[No.(2020)3]。
文摘Objective:To evaluate clinical efficacy by traditional Chinese combined with western therapy to treat upper extremity edema after breast cancer surgery.The clinical efficacy was described by the effective rate and the change of peripheral diameter of the affected limb.Methods:National Knowledge Internet(CNKI),Wan Fang Digital Journals(Wan Fang),VIP Chinese periodical service platform(VIP),Chinese biomedical literature service system(CBM),PubMed and EMBASE were searched on computer.And clinical randomized controlled trials(RCT)of the treatment of upper extremity edema after breast cancer surgery with integration of Chinese and western treatment were selected.The time was from January 2011 to May 2020.Upper extremity edema after breast cancer surgery was the first key word and the second was traditional Chinese combined with western therapy.Note Express was used to screen and extract literature.Bias risks of all the literature included in the study were evaluated and analyzed by RevMan5.3 software.Results:10 randomized controlled clinical tests,644 patients in conformity to the inclusion criteria,9 for the observation of curative effectiveness,5 of changes in limb circumference.322 cases were included in the observation group and the same number of cases in the control group,all of which were in Chinese.The results expressed that the curative effect in the observation group was 91.1%,and it was higher than the curative effect in the control group treated by single western treatment obviously,and it was only 68.9%[95%CI(1.22,1.44),Z=6.55,P<0.00001].The peripheral diameter shrinking degree of the affected limb in the observation group was also clearly higher than that in the control group which was healed by simple western treatment[95%CI(-0.98,-0.64),Z=9.40,P<0.00001].Conclusion:Traditional Chinese combined with western therapy treating upper extremity edema after the surgery of breast cancer had a notable clinical effect,which treated the disease and effectively lessened the peripheral diameter of the affected limb.The method was worthy of clinical application.However,owing to the low quality of the included documents,further discussion and learning were still needed.
文摘Objective To observe the clinical efficacy and safety of WenYang HuoXue Washing Prescription （WYHX） in the treatment of upper limb edema after breast cancer surgery. Methods： Seventy-eight patients with upper extremity edema after operation of breast cancer with Yin Syndrome were given wet compress with prescription and nursing guidance. The symptom score of affected extremity was observed before and 14 days after treatment, and the total effective rate was evaluated. Results： Twenty-three cases were markedly effective, 41 cases were effective and 14 cases were Invalid. The total effective rate was 82.1%. There was no significant difference between the two groups according to stage I and stage II of edema （P 〉 0.05）. Conclusion： WYHX can effectively improve the discomfort symptoms of upper limb edema and cold after breast cancer surgery, and is worthy of clinical application.
文摘目的:探讨身体质量指数(body mass index,BMI)与放疗前、后乳腺癌相关淋巴水肿(breast cancer related lymphedema,BCRL)的相关性。方法:分析2013年11月至2015年2月281例于河北医科大学第四医院收治的单侧乳腺癌术后女性患者的前瞻性临床资料,根据BMI<25、25~27、BMI≥28分为BMI低组(n=94)、中组(n=89)、高组(n=98),比较健患侧上肢体积差(upper limb volume difference,ULVD),采用广义估计方程(GEE)模型和线性逻辑回归模型进行单因素和多因素分析,评估放疗对BCRL(定义为ULVD≥200 m L)的影响,并与其他BMI分界值分组结果进行比较。结果:放疗前、后ULVD平均值分别为40.6、42.9 m L,中位值均为30.0 m L,二者之间差异无统计学意义(P>0.05)。放疗前(2例缺失)BMI低、中、高组的BCRL发生率分别为2.2%(2/93)、6.8%(6/88)、13.3%(13/98),放疗后(1例缺失)分别为1.1%(1/93)、12.4%(11/89)、12.2%(12/98),GEE模型多因素分析显示放疗未增加BCRL率(P=0.529)。线性逻辑回归模型多因素分析显示,与BMI低组相比中组和高组放疗前(RR=4.199,P=0.693和RR=10.999,P=0.002)、放疗后(RR=13.287,P=0.047和RR=14.308,P=0.029)的BCRL发生率差异具有统计学意义。按BMI<25、25~29、BMI≥30分组,分析结果与以上类似。结论:乳腺癌患者术后放疗发生BCRL,中国乳腺癌患者理想的BMI<28,与国外欧美患者为主的BMI<30不同。
